Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Adma Biologics (ADMA) EBT: 2011-2025

Historic EBT for Adma Biologics (ADMA) over the last 12 years, with Sep 2025 value amounting to $47.5 million.

  • Adma Biologics' EBT rose 29.30% to $47.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $155.8 million, marking a year-over-year increase of 112.35%. This contributed to the annual value of $125.7 million for FY2024, which is 545.18% up from last year.
  • As of Q3 2025, Adma Biologics' EBT stood at $47.5 million, which was up 18.50% from $40.1 million recorded in Q2 2025.
  • Adma Biologics' EBT's 5-year high stood at $47.5 million during Q3 2025, with a 5-year trough of -$18.8 million in Q2 2021.
  • Over the past 3 years, Adma Biologics' median EBT value was $33.5 million (recorded in 2025), while the average stood at $19.9 million.
  • Its EBT has fluctuated over the past 5 years, first slumped by 49.63% in 2023, then surged by 1,332.71% in 2024.
  • Quarterly analysis of 5 years shows Adma Biologics' EBT stood at -$16.5 million in 2021, then rose by 28.55% to -$11.8 million in 2022, then crashed by 49.63% to -$17.6 million in 2023, then skyrocketed by 296.73% to $34.7 million in 2024, then climbed by 29.30% to $47.5 million in 2025.
  • Its EBT stands at $47.5 million for Q3 2025, versus $40.1 million for Q2 2025 and $33.5 million for Q1 2025.